Skip to content
2000
Volume 20, Issue 8
  • ISSN: 1573-4129
  • E-ISSN: 1875-676X

Abstract

Objective

A novel stability indicating RP-HPLC method was developed and validated for the simultaneous estimation of Pregabalin and Duloxetine by using the QBD approach.

Methods

To determine the optimal parameters for the duloxetine and pregabalin study, we used Design Expert version 13.0 in this work. The mobile phase consisted of 0.8 ml/min of methanol: water (80:20, v/v) with o-phosphoric acid-adjusted pH 3.A 250 mm × 4.6 mm ID, 5 µm particle size Cosmosil C18 column was used. The UV-3000-M detector was used to detect at 218 nm.

Results

Duloxetine's retention time was 7.153 ± 0.1 min, whereas Pregabalin's was 4.481±0.1 min. The ICH parameters like linearity, accuracy, robustness, ruggedness, LOD and LOQ, and system suitability were determined. Likewise, the tailing factors were found to be 1.27 and 1.26, while the theoretical plates of duloxetine and pregabalin were found to be 8313 and 8549, respectively. The recovery study shows the results (99.37–99.84% for pregabalin and 99.03–99.74% for duloxetine), and the precision was obtained with a %RSD of less than 2%. The result of the assay was 99.92% for pregabalin and 99.39% for duloxetine. The developed method was used for the forced degradation study. The Box-Behnken design experiment using Design Expert 13.0 was adopted for the QBD approach.

Conclusion

All the values obtained for different parameters were within the acceptable range of ICH. The developed method can be routinely used for the simultaneous estimation of Pregabalin and Duloxetine by using the QBD approach.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpa/10.2174/0115734129321062240906070516
2024-09-16
2025-09-01

  • From This Site

    /content/journals/cpa/10.2174/0115734129321062240906070516
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. OjashP. MonaP. Development and validation of novel RP-HPLC method for simultaneous analysis of pregabalin and duloxetine in synthetic mixture.Int. J. Pharm. Sci. Res.2023141153735379
     [Google Scholar]
  2. SathyaprakashR.N RavichandranS. Method development and validation for the simultaneous estimation of pregabalin and duloxetine HCl in bulk and pharmaceutical dosage form by UV and RP-HPLC using human plasma.Int J Novel Res Develop202381871882
     [Google Scholar]
  3. ChavanS. D. PimpodkarN.V. KadamA.S. GaikwadP.S. Quality by design, research and reviews.J Pharm Qual Assur121824
     [Google Scholar]
  4. JoshiA. RajputA. VermaP. SrivastavaS.P. SharmaU. MishraS. Quality by design – A tool for pharmaceutical industry that has no near end.Int. J. Pharm. Res.20211337785
     [Google Scholar]
  5. ChandrakantsingP. ShevalkarG. BariD. SinghaiV. KapadiaR. DasU. Introduction to quality by design.Precepts and fundamental Aspects of quality by Design (QbD): From theory to practice.Springer202410.1007/978‑981‑99‑8034‑5_1
     [Google Scholar]
  6. PatelK. ShahU.A. PatelC.N. Box–Behnken design – assisted optimization of RP-HPLC method for the estimation of evogliptin tartrate by analytical quality by design.Future J. Pharm. Sci.2023957112
     [Google Scholar]
  7. ShailendraS. PalledM.S. Box-behnken design assisted optimization and standardization of chromatographic methodology for quality assessment of metformin: Analytical quality by design avenue.Indian J. Pharm. Educ. Res202256s152s16210.5530/ijper.56.2s.86.
     [Google Scholar]
  8. KarmarkarS. GarberR. GenchanokY. GeorgeS. YangX. HammondR. Quality by design (QbD) based development of a stability indicating HPLC method for drug and impurities.J. Chromatogr. Sci.201149643944610.1093/chrsci/49.6.43921682993
     [Google Scholar]
  9. International Conference on Harmonization (ICH), Q2 (R1) Pharmaceutical Development2005
     [Google Scholar]
  10. KrunalY. DedaniaZ.R. DedaniaR.R. PatelU. QbD approach to HPLC method development and validation of ceftriaxone sodium.Fut J Pharm Sci20217110.1186/s43094‑021‑00286‑4.
     [Google Scholar]
  11. GuptaI. AdinS.N. AqilM. MujeebM. AkhtarM. Application of QbD‐based approach to the development and validation of an RP‐HPLC method for simultaneous estimation of pregabalin and naringin in dual‐drug loaded liposomes.Biomed. Chromatogr.2023376e562310.1002/bmc.562336919518
     [Google Scholar]
  12. ArafaM.G. AyoubB.M. DOE optimization of nano-based carrier of pregabalin as hydrogel: New therapeutic & chemometric approaches for controlled drug delivery systems.Sci. Rep.2017714150310.1038/srep4150328134262
     [Google Scholar]
  13. SheladiaS. PatelB. Implementation of QBD approach to develop and validate analytical method for simultaneous estimation of duloxetine hydrochloride and methylcobalamin in pharmaceutical dosage form by HPTLC method.Int. J. Pharm. Pharm. Sci.201687105113
     [Google Scholar]
  14. YuL.X. Pharmaceutical quality by design: Product and process development, understanding, and control.Pharm. Res.200825478179110.1007/s11095‑007‑9511‑118185986
     [Google Scholar]
  15. MonksK.E. RiegerH.J. MolnárI. Expanding the term “Design Space” in high performance liquid chromatography (I).J. Pharm. Biomed. Anal.201156587487910.1016/j.jpba.2011.04.01521893394
     [Google Scholar]
  16. KrullI. SwartzM. TurpinJ. LukulayP.H. VerseputR. A quality-by-design methodology for rapid LC method development, part-I.LC GC N. Am.20082611901197
     [Google Scholar]
  17. TurcotteJ. DebonnelG. de MontignyC. HébertC. BlierP. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.Neuropsychopharmacology200124551152110.1016/S0893‑133X(00)00220‑711282251
     [Google Scholar]
  18. ChalonS.A. GranierL.A. VandenhendeF.R. BieckP.R. BymasterF.P. JoliatM.J. HirthC. PotterW.Z. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: A double-blind, controlled study.Neuropsychopharmacology20032891685169310.1038/sj.npp.130020912784100
     [Google Scholar]
  19. Chandana MS. KS. AA. NarendraP. KS. QbD-based stability-indicating rp-hplc method development and validation for the estimation of favipiravir—An eco-friendly approach.J. AOAC Int.2024107337738610.1093/jaoacint/qsae00938318977
     [Google Scholar]
  20. PratikshaS. JenishM. ZarnaD. RonaD. QbD approach for stability indicating hplc method for determination of artemether and lumefantrine in combined dosage form.Int. J. Drug Regul. Aff.201754445910.22270/ijdra.v5i4.209
     [Google Scholar]
  21. GavinP.F. OlsenB.A. A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603).J. Pharm. Biomed. Anal.200846343144110.1016/j.jpba.2007.10.03718082352
     [Google Scholar]
  22. PohlM. BormanP. SchweitzerM. SmithK. HansenG. LarewJ. Hanna-BrownM. NethercoteP. Implications and opportunities of applying the principles of QBD to analytical measurements.Pham Technol (Europe)2010222937
     [Google Scholar]
  23. SchweitzerM. PohlM. Hanna-BrownM. NethercoteP. BormanP. HansenG. SmithK. LareJ. Implications and opportunities of applying QBD principles to analytical measurements.Pham Technol (Europe)2010345259
     [Google Scholar]
  24. LiY. LiuD.Q. YangS. SudiniR. McGuireM.A. BhanushaliD.S. KordA.S. Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping.J. Pharm. Biomed. Anal.201052449350710.1016/j.jpba.2010.01.04320189340
     [Google Scholar]
  25. Huynh-BaK. Pharmaceutical Stability Testing to Support Global Markets201010.1007/978‑1‑4419‑0889‑6.
     [Google Scholar]
  26. MechamS. RancourtC. Applying QbD based on risk assessment to achieve a fundamental and practical understanding of method validation.IVT conference on Method ValidationSan Francisco2010
     [Google Scholar]
  27. EnriqueM. García-MontoyaE. MiñarroM. OrriolsA. TicóJ.R. Suñé-NegreJ.M. Pérez-LozanoP. Application of an experimental design for the optimization and validation of a new HPLC method for the determination of vancomycin in an extemporaneous ophthalmic solution.J. Chromatogr. Sci.200846982883410.1093/chromsci/46.9.82819007487
     [Google Scholar]
  28. PippallaS. NekkalapudiA.R. JillellamudiS.B. Stability indicating RP-UPLC method for quantification of glycopyrrolate, methylparaben and propylparaben assay in liquid oral formulation.Am. J. Anal. Chem.202213538552
     [Google Scholar]
/content/journals/cpa/10.2174/0115734129321062240906070516
Loading
Simultaneous Estimation of Pregabalin and Duloxetine, Used to Treat Nerve Pain, by Stability Indicating RP-HPLC Method Using the QBD Approach
Current Pharmaceutical Analysis 20, 833 (2024); https://doi.org/10.2174/0115734129321062240906070516
/content/journals/cpa/10.2174/0115734129321062240906070516
/content/journals/cpa/10.2174/0115734129321062240906070516
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): duloxetine; forced degradation; Pregabalin; QBD approach; quality by design; RP-HPLC

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test